Protagonist Therapeutics Stock Forecast, Price & News

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTGX stock has increased by 158.4% and is now trading at $18.50.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protagonist Therapeutics.

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Protagonist Therapeutics.

Protagonist Therapeutics Inc (NASDAQ:PTGX) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.02. The firm earned $6.22 million during the quarter, compared to analysts' expectations of $3.80 million. Protagonist Therapeutics had a negative return on equity of 72.42% and a negative net margin of 438.96%.
View Protagonist Therapeutics' earnings history.

5 brokers have issued twelve-month price targets for Protagonist Therapeutics' shares. Their forecasts range from $27.00 to $33.00. On average, they expect Protagonist Therapeutics' stock price to reach $31.20 in the next year. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics.

Protagonist Therapeutics saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 2,740,000 shares, a drop of 16.5% from the September 30th total of 3,280,000 shares. Based on an average daily trading volume, of 348,600 shares, the short-interest ratio is presently 7.9 days.
View Protagonist Therapeutics' Short Interest.

Some companies that are related to Protagonist Therapeutics include Opko Health (OPK), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), Axsome Therapeutics (AXSM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), I-Mab (IMAB), Aimmune Therapeutics (AIMT), Pacira BioSciences (PCRX), Seres Therapeutics (MCRB), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Karuna Therapeutics (KRTX), Aurinia Pharmaceuticals (AUPH) and Madrigal Pharmaceuticals (MDGL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.06%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Richard S Shames and Suneel Gupta.
View institutional ownership trends for Protagonist Therapeutics.

PTGX stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC.
View insider buying and selling activity for Protagonist Therapeutics.

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTGX stock can currently be purchased for approximately $18.50.

Protagonist Therapeutics has a market capitalization of $680.93 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]